Courthouse News reports:
An independent advisory panel for the U.S. Centers for Disease Control and Prevention voted Friday to recommend the continued use of the Johnson & Johnson Covid-19 vaccine after the single-dose jab was put on pause over blood clotting concerns.
Friday’s vote followed similar concerns in the Europe Union over both the J&J jab and the AstraZeneca vaccine, which also faced concerns over blood clots.
Like AstraZeneca, the European Medicines Agency found a link between the J&J vaccine and very rare cases of blood clots, but said its benefits far outweigh the risks. EU member states began administering the shot this week.
Read the full article.
— CNBC (@CNBC) April 23, 2021